Table Topics and Facilitators
Clinical Decision-Support Software: Assessing the Impact of FDA’s New Guidance
Bradley Merrill Thompson, Partner
Epstein Becker & Green, PC
Status Report on FDA’s Regulation of Cannabis Products
Madeleine Giaquinto, Director of Regulatory Affairs,
Greenleaf Health, Inc.
Does FDA Have Sufficient Product Information and Scientific Expertise to Make PMTA Decisions?
Jim Solyst, Principal
JMS Scientific Engagement